Aurobindo Pharma Ltd. announced on Wednesday that a new injectable facility of Eugia Steriles Private Ltd., which was inspected by the US Food and Drug Administration, received its first product approval, according to the firm's press release.
Eugia Steriles Private Limited is a 100% subsidiary of Eugia Pharma Specialities Limited and a step-down subsidiary of Aurobindo Pharm.
The plant located in Andhra Pradesh was inspected by the USFDA from March 28 to April 5 of this year.
The FDA approved Lidocaine Hydrochloride Injection, USP, 1% (10 mg/mL) and 2% (20 mg/mL).
The supplemental Abbreviated New Drug Application for the product was submitted as 'Prior Approval Supplement' for the addition of an alternate drug product manufacturing, labelling, packaging, and testing facility.
(With Inputs From PTI)
RECOMMENDED FOR YOU

Alembic Pharma Gets USFDA Nod For Generic Drug To Treat Depression, Anxiety


Aurobindo Pharma Eyes 'Significant Portion' Of $7 Billion Osteoporosis Drug Market


USFDA Issues Form 483 With Eight Observations To Aurobindo's Telangana Unit


Microsoft Launches MAI-1-Preview, MAI-Voice-1 AI Models: Features, Performance And Other Key Details
